Overview
Takeda is a research-based global pharmaceutical company. It is the largest pharmaceutical company in Japan and one of the global leaders of the industry. Setting our management philosophy, “Takeda-ism” as the basis of business, Takeda is committed to striving towards better health for patients worldwide through leading innovation in medicine.
Takeda is enhancing its R&D pipeline by concentrating its management resources.
Takeda's in-house ethical drugs are marketed in around 90 countries worldwide and are recognized as the brand in major countries worldwide.
General Information
| Company Name | Takeda Pharmaceutical Company Limited |
| Headquarters Head Office | 1-1, Doshomachi 4-chome, Chuo-ku, Osaka 540-8645 TEL: +81 6 6204-2111 FAX: +81 6 6204-2880 |
| Tokyo Head Office | 12-10, Nihonbashi 2-chome, Chuo-ku, Tokyo 103-8668 TEL: +81 3 3278-2111 FAX: +81 3 3278-2000 |
| Founded | June 12, 1781 |
| Incorporated | January 29, 1925 |
| President | Yasuchika Hasegawa |
| Paid-In Capital | ¥63.5 billion |
| Number of Employees | 6,471 (parent), 18,498 (consolidated) |
| Number of Shareholders | 256,291 |
| Scope of Business | Manufacturing, marketing and import / export of pharmaceutical drugs, etc. |
| R&D Facilities | Osaka, Tsukuba (Japan), Palo Alto, San Diego, San Francisco, Deerfield（U.S.）, London, Cambridge（U.K.）, Singapore |
| Production Facilities | Osaka, Hikari, Italy, Ireland, China, Indonesia |
| Overseas Subsidiaries and affiliates | U.S., Canada, U.K., France, Italy, Germany, Austria, Switzerland, Spain, Portugal, Ireland, Netherlands, Sweden, Belgium, Turkey, China, Taiwan, Philippines, Thailand, Indonesia, Singapore, Mexico, Brazil, Korea |
Organization of Takeda Pharmaceutical Company Limited (As of January 18, 2012)
 |
Financial Highlights
| FY2010 | FY 2009 | |
| Net Sales | ¥1,419.4 billion (US$17,101 million) |
¥1,466 billion (US$15,763 million) |
| Net Income | ¥247.9 billion (US$2,986 million) |
¥297.7 billion (US$3,202 million) |
| R&D Investment | ¥288.9 billion (US$3,480 million) |
¥296.4billion (US$3,187 million) |
| Earnings Per Share | ¥314.01 (US$3.78) |
¥377.19 (US$4.06) |
| Dividends Per Share | ¥180.00 (US$2.17) |
¥180.00 (US$1.94) |
| Consolidated Subsidiaries | 61 companies | 55 companies |
| Affiliated Companies Accounted for by the Equity Method |
14 companies | 15 companies |
[*]Note: The U.S. dollar amounts represent translations of Japanese yen, for convenience only, at the rate of ¥98=US$1 for FY 2008 and ¥100=US$1 for FY 2007.
Stock
Performance
02/03 15:00 (TSE 1st)
- Value
- 3,320 JPY
- Net change
- -15 JPY
- JIJI PRESS,LTD
Access
Head Office
Tokyo Head Office
Osaka Research Center
Related Links
Annual Report
| PDF 10.8MB 152P |
